PMID- 31189966
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20231012
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Jun 12
TI  - Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A 
      Nationwide, Nested, Case-Control Study.
PG  - 8532
LID - 10.1038/s41598-019-44447-1 [doi]
LID - 8532
AB  - Several studies have shown that the use of sulfonylureas in patients with type 2 
      diabetes mellitus (T2DM) is associated with a higher risk of hepatocellular 
      carcinoma (HCC). In this study, we investigated the effects of individual 
      sulfonylureas on HCC development using the National Health Insurance 
      Service-National Sample Cohort in South Korea. Among 47,738 subjects aged 40 
      years or older who had newly diagnosed with diabetes, 241 incident HCC cases and 
      1205 matched controls were identified. Adjusted odds ratios (ORs) as estimates of 
      the relative risk of HCC were calculated using logistic regression analysis. 
      Compared to patients never treated with a sulfonylurea, those treated with a 
      sulfonylurea had a 1.7-fold increased risk of HCC development. Of the different 
      types of sulfonylureas, the exclusive use of glimepiride was associated with a 
      significantly elevated risk of HCC (OR = 1.89, 95% CI = 1.02-3.47) compared to 
      those who were never treated with sulfonylureas. No significant associations were 
      observed between exclusive gliclazide use and incident HCC (OR = 2.04, 95% 
      CI = 0.75-5.52). In conclusion, the association between the use of sulfonylureas 
      and risk of HCC was different according to the type of sulfonylurea, in patients 
      with new-onset T2DM. Further prospective studies are warranted to confirm these 
      results and translate them into clinical practice.
FAU - Lee, Ji-Yeon
AU  - Lee JY
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Jang, Suk-Yong
AU  - Jang SY
AD  - Department of Preventive Medicine, Eulgi University College of Medicine, Daejeon, 
      Republic of Korea.
FAU - Nam, Chung Mo
AU  - Nam CM
AD  - Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea. cmnam@yuhs.ac.
FAU - Kang, Eun Seok
AU  - Kang ES
AUID- ORCID: 0000-0002-0364-4675
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea. edgo@yuhs.ac.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190612
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Sulfonylurea Compounds)
RN  - 6KY687524K (glimepiride)
RN  - G4PX8C4HKV (Gliclazide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carcinoma, Hepatocellular/chemically induced/epidemiology
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Female
MH  - *Gliclazide/administration & dosage/adverse effects
MH  - Humans
MH  - Incidence
MH  - *Liver Neoplasms/chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Republic of Korea/epidemiology
MH  - Risk Factors
MH  - *Sulfonylurea Compounds/administration & dosage/adverse effects
PMC - PMC6561966
COIS- The authors declare no competing interests.
EDAT- 2019/06/14 06:00
MHDA- 2020/10/21 06:00
PMCR- 2019/06/12
CRDT- 2019/06/14 06:00
PHST- 2018/10/05 00:00 [received]
PHST- 2019/05/17 00:00 [accepted]
PHST- 2019/06/14 06:00 [entrez]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/06/12 00:00 [pmc-release]
AID - 10.1038/s41598-019-44447-1 [pii]
AID - 44447 [pii]
AID - 10.1038/s41598-019-44447-1 [doi]
PST - epublish
SO  - Sci Rep. 2019 Jun 12;9(1):8532. doi: 10.1038/s41598-019-44447-1.